The abstract is read at the publisher; the summary is JClub's.
Higher tumor-compartment SPP1 expression is linked to worse overall survival in an independent real-world advanced gastric cancer immunotherapy cohort of 137 patients.
- Why it matters: PD-L1 alone does not fully reflect tumor–immune context, and treatment benefit varies within PD-L1 strata, motivating additional spatial biomarkers for chemoimmunotherapy response.
- What they did: Using spatially resolved transcriptome profiling across 70 trial patients and 137 real-world patients (794 regions of interest; 1,337 tumor/immune areas), the study tested SPP1, CXCL8, and IL1B differences between durable and no clinical benefit groups.
- The result: In the phase II trial, SPP1 (with CXCL8 and IL1B) was significantly downregulated in the tumor compartment in durable clinical benefit versus no clinical benefit, and plasma proteomics showed lower circulating SPP1 in durable responders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.